In the pooled trials where CRP fell, people mostly took 1,000 to 4,000 IU of vitamin D a day for at least 3 months, and the clearest drops came in people with blood sugar problems. More did not help more: in the one head-to-head trial, 4,000 IU a day moved CRP no better than 400. In overweight adults, no dose moved it.
The numbers
CRP, or C-reactive protein, is a protein your liver releases when there is inflammation somewhere in the body. Labs report it in milligrams per liter (mg/L). Vitamin D doses come in international units (IU), though some papers use micrograms. One microgram is 40 IU, so the 100 microgram cutoff in the arthritis trials below is 4,000 IU a day.
| Who was studied | Daily dose | How long | What CRP did | Source |
|---|---|---|---|---|
| Healthy adults, 9 high-quality trials | under 1,000 IU, or 1,000 IU and up | 12 weeks or longer | Under 1,000 IU: up 0.6 mg/L. 1,000 IU and up: down 0.9 mg/L. All 9 pooled: no change | |
| Adults with low vitamin D, 289 people (the DAYLIGHT trial) | 400 IU vs 4,000 IU | 6 months | No difference between the two doses | |
| Type 2 diabetes, 20 trials, 1,270 people | any dose | any length | Lower. Dose and length of treatment did not change the result | |
| Overweight or obese adults, 11 trials, 504 people | 1,000 to 7,000 IU, or single doses of 100,000 to 200,000 IU | 2 to 26 weeks | No change at any dose | |
| Postmenopausal women, 7 studies | varied; one subgroup at 1,000 IU or less | best past 3 months | Down 0.65 mg/L overall; down 2.10 mg/L in the 1,000 IU or less trials | |
| Rheumatoid arthritis, 11 studies, 3,049 patients | under or over 100 micrograms (4,000 IU) | varied | No clear change overall; the higher doses did more |
One more number helps. In the DAYLIGHT trial, 4,000 IU a day raised the blood level of 25-hydroxyvitamin D, the form labs measure, by 15.5 ng/mL over 6 months. The 400 IU group rose by 4.6. That gap is 10.9 ng/mL for 3,600 extra IU a day, so each extra 1,000 IU bought about 3 ng/mL of blood level. That is our arithmetic, not the trial's. The dose moved the blood level. CRP did not follow.
What moves the number
Not the dose, as far as anyone can tell. What seemed to matter was who was taking it.
The blood levels separated. The inflammation markers did not.From a 2021 randomized trial in J Am Heart Assoc
Your blood sugar. A 2026 umbrella review of 97 trials, about 11,600 people, found the clearest CRP drops in people with abnormal blood sugar control. A pooled analysis of 20 diabetes trials, 1,270 people, found lower CRP and lower TNF-alpha in the vitamin D groups. IL-6 did not move.
Your weight. In overweight and obese adults, trials tried 1,000 to 7,000 IU a day and single doses of up to 200,000 IU. CRP, IL-6 and TNF-alpha stayed put, even where blood levels clearly rose.
Your starting level. DAYLIGHT only enrolled adults at or under 25 ng/mL, and even there the higher dose did no better. In healthy adults, trials that pushed blood levels to 80 nmol/L or more (32 ng/mL, since labs divide by 2.5) showed a trend toward lower CRP that fell short of significance. In type 2 diabetes, starting level made no difference.
Is there an anti-inflammatory dosage of vitamin D?
If there were a clean one, the pooled trials would agree on it. They do not. In healthy adults, 1,000 IU or more a day beat lower doses on CRP, and in rheumatoid arthritis, doses above 4,000 IU did more than lower ones. So far, more looks better.
Then it flips. In postmenopausal women, the biggest CRP drop came from the trials at 1,000 IU or less. In type 2 diabetes, dose and duration did not alter the results at all. And in the one trial built to settle it, 289 adults with low vitamin D took 400 or 4,000 IU a day for 6 months. The blood levels separated. The inflammation markers did not.
The 2024 Endocrine Society panel said it plainly: trial doses varied so much, and so many participants kept taking their own supplements, that the best dose remains unclear. What the trials hand you is a range, 1,000 to 4,000 IU a day, and no ladder inside it.
When a number should worry you
Two numbers to watch: your blood level and your daily dose.
The blood level. The 2011 Institute of Medicine report set the bar at 20 ng/mL (50 nmol/L). That level meets the needs of at least 97.5% of people. It rests on bone health, not inflammation. Getting there takes about 600 IU a day up to age 70, and 800 IU from 71 on. Above that line the report found no consistent extra benefit, and for some outcomes a U-shaped curve, with risk rising at both the low and the high end. The 2024 guideline found no clear evidence for an optimal target level and suggests against routine blood testing without a medical reason.
The dose. One published case gives the scale. A 56-year-old woman on an unconventional protocol for multiple sclerosis took, on average, 130,000 IU a day for 20 months. She arrived at hospital with nausea, vomiting and muscle weakness, a blood level of 920 nmol/L (368 ng/mL), dangerously high calcium and failing kidneys. A week after she stopped, her calcium was normal, but her kidneys took about 6 months to recover and her vitamin D level took 18 months.
Set that against the table above: 130,000 divided by 4,000 is about 32. She took 32 times the highest trial dose, every day, for nearly two years. The case authors' own conclusion was that clinical doses are far lower and intoxication is rare. Even planned megadoses under medical care raised calcium in the blood or urine in 1.9% to 18.5% of patients across 10 studies. That is the ceiling. It is nowhere near 4,000 IU.
What to do with your number
Tick what you'll try this week. Your picks stay on this device.
you have kidney disease or a history of kidney stones, you have ever had high blood calcium, you are pregnant, you take calcium supplements or a medicine that affects calcium, someone has suggested a high-dose vitamin D protocol for a condition such as multiple sclerosis, or you are 75 or older and already take vitamin D.
One tap. Results appear once 50 readers have voted, and the count is always real.
Common questions
Does vitamin D reduce inflammation in the body?
A little, on average, and mostly in certain people. Across 23 meta-analyses, vitamin D supplements lowered CRP and TNF-alpha but not IL-6. A 2026 umbrella review found the drops concentrated in people with blood sugar problems, with no change in overweight or asthmatic groups. High-quality trials in healthy adults found no effect.
Is vitamin D3 anti-inflammatory?
Vitamin D3, or cholecalciferol, is the form most trials used. In 9 high-quality trials of healthy adults, it did not lower CRP or IL-6 overall, and in the DAYLIGHT trial 4,000 IU of D3 a day did no better than 400. The form is not the problem.
Can vitamin D cause inflammation in joints?
The trials point the other way. In 11 studies of 3,049 people with rheumatoid arthritis, vitamin D lowered pain scores and a joint disease activity score, though not CRP overall. The harm from too much is high blood calcium and kidney injury, not joint inflammation. New joint pain after starting a supplement is still worth a call to your provider.
Reader stories
What happened for you?
Studies tell us what works on average. You know what happened in your own body. Share it here, and the next person who reads this page gets something no study can give them.
A reader who shared their story here sent you this article. When you're ready, add yours.
Ask the Research Desk
Heard something about inflammation you want checked? The best questions become articles, credited by first name only if you say yes.
How this article was made
Researched and written from 13 peer-reviewed papers. Our automated check matched every claim against the exact words of its source, confirmed every paper exists in PubMed, and found none retracted. Checked November 3, 2026. Not individually reviewed by a doctor. Photos are illustrative; the people in them are not patients or readers.
Grades run Strong, Moderate, Emerging, Early and Not supported, and the grade decides the words we may use. How we grade evidence · Medical disclaimer
Sources
- Umbrella reviewThe effects of vitamin D supplementation on inflammatory biomarkers: an umbrella study of meta-analysis on randomized controlled trials.Hsu CY, Hussein HY, Al-Akkam KA et al. Inflammopharmacology, 2026.PubMedFull paper
- Meta-analysisEfficacy of vitamin D supplementation as an adjunct therapy for improving inflammatory and oxidative stress biomarkers: An umbrella meta-analysis.Moslemi E, Musazadeh V, Kavyani Z et al. Pharmacol Res, 2022.PubMedFull paper
- Meta-analysisThe impact of cholecalciferol supplementation on the systemic inflammatory profile: a systematic review and meta-analysis of high-quality randomized controlled trials.Calton EK, Keane KN, Newsholme P et al. Eur J Clin Nutr, 2017.PubMedFull paper
- Meta-analysisVitamin D supplementation does not alter inflammatory markers in overweight and obese individuals: A systematic review and meta-analysis of randomized controlled trials.Gouveia HJCB, da Silva MM, Manhães de Castro R et al. Nutr Res, 2024.PubMedFull paper
- Meta-analysisVitamin D supplementation for improvement of chronic low-grade inflammation in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.Mousa A, Naderpoor N, Teede H et al. Nutr Rev, 2018.PubMedFull paper
- Randomized trialEffects of Vitamin D Supplementation on Cardiovascular and Glycemic Biomarkers.Miao J, Bachmann KN, Huang S et al. J Am Heart Assoc, 2021.PubMedFull paper
- Meta-analysisThe Effects of Vitamin D Supplementation on C-Reactive Protein and Systolic and Diastolic Blood Pressure in Postmenopausal Women: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.Jiang Q, Prabahar K, Saleh SAK et al. J Acad Nutr Diet, 2024.PubMedFull paper
- Meta-analysisEffect of vitamin D on inflammatory and clinical outcomes in patients with rheumatoid arthritis: a systematic review and dose-response meta-analysis of randomized controlled trials.Al-Saoodi H, Kolahdooz F, Andersen JR et al. Nutr Rev, 2024.PubMedFull paper
- Meta-analysisThe effect of vitamin d-calcium co-supplementation on inflammatory biomarkers: A systematic review and meta-analysis of randomized controlled trials.Asbaghi O, Sadeghian M, Mozaffari-Khosravi H et al. Cytokine, 2020.PubMedFull paper
- StudyThe 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know.Ross AC, Manson JE, Abrams SA et al. J Clin Endocrinol Metab, 2011.PubMedFull paper
- GuidelineVitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline.Demay MB, Pittas AG, Bikle DD et al. J Clin Endocrinol Metab, 2024.PubMedFull paper
- Systematic reviewSafety and effectiveness of vitamin D mega-dose: A systematic review.Ataide FL, Carvalho Bastos LM, Vicente Matias MF et al. Clin Nutr ESPEN, 2021.PubMedFull paper
- ReviewHow Much Vitamin D is Too Much? A Case Report and Review of the Literature.De Vincentis S, Russo A, Milazzo M et al. Endocr Metab Immune Disord Drug Targets, 2021.PubMedFull paper
